Advertisement

Breast Cancer Research and Treatment

, Volume 88, Issue 2, pp 103–108 | Cite as

Response to fulvestrant in heavily pretreated postmenopausal women:a single-center experience

  • Sandra Franco
  • Alejandra Perez
  • Elizabeth Tan-chiu
  • Cynthia Frankel
  • Charles L. Vogel
Article

Abstract

Fulvestrant (`Faslodex') is a new estrogen receptor (ER) antagonist that has no agonist effects. It binds, blocks and accelerates degradation of the ER, leading to a complete abrogation of estrogen-sensitive gene transcription. In postmenopausal women with advanced breast cancer progressing on prior endocrine therapy, fulvestrant is at least as effective as the third-generation aromatase inhibitor (AI) anastrozole.In this single-center experience, 42 postmenopausal patients with metastatic breast cancer who had been heavily pretreated with prior endocrine therapy and chemotherapy were treated with fulvestrant. Prior endocrine therapies included selective ER modulators (including tamoxifen and toremifene), AIs, megestrol acetate, and high-dose estrogens. In total, eight patients (19%) achieved stable disease (SD) for ≥24 weeks, including two patients with SD for 2 years and one with SD for 14 months. Fulvestrant was well tolerated with the majority of adverse events related to the site of metastatic disease.These data demonstrate that fulvestrant is a well tolerated and effective endocrine therapy for postmenopausal women with metastatic breast cancer who have been heavily pretreated with prior therapies. The novel mechanism of action of fulvestrant reduces the likelihood of cross-resistance with other endocrine therapies and therefore this agent may be active in patients who have proved to be resistant to treatments such as tamoxifen or AIs. The use of fulvestrant earlier in the sequence of endocrine treatments may achieve better responses than observed in this heavily pretreated patient population.

endocrine therapy estrogen receptor `Faslodex' fulvestrant postmenopausal 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wakeling AE: Use of pure antioestrogens to elucidate the mode of action of oestrogens. Biochem Pharmacol 49: 1545–1549, 1995Google Scholar
  2. 2.
    Wakeling AE: Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer 7: 17–28, 2000Google Scholar
  3. 3.
    Wakeling AE, Dukes M, Bowler J: A potent specific pure antiestrogen with clinical potential. Cancer Res 51: 3867–3873, 1991Google Scholar
  4. 4.
    Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A: Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 20: 3386–3395, 2002Google Scholar
  5. 5.
    Howell A, Robertson JFR, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C: Fulvestrant,formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 20: 3396–3403, 2002Google Scholar
  6. 6.
    Robertson JF, Osborne CK, Howell A, Jones SE, Mauriac L, Ellis M, Kleeberg UR, Come SE, Vergote I, Gertler S, Buzdar A, Webster A, Morris C: Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women-a prospective combined analysis of two multicenter trials. Cancer 98: 229–238, 2003Google Scholar
  7. 7.
    Perey L, Thürlimann B, Hawle H, Bonnefoi H, Ahern J, Pagani O, Goldhirsch A, Dietrich D: Fulvestrant ('Faslo-dex ') as hormonal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamoxifen and aromatase inhibitors. Breast Cancer Res Treat 76(Suppl. 1): S72, 2002 (abstract 249)Google Scholar
  8. 8.
    Howell A: Postmenopausal women with advanced breast cancer who progress on fulvestrant or tamoxifen retain sensitivity to further endocrine therapies. Breast Cancer Res Treat 76(Suppl. 1): S72, 2002 (abstract 251)Google Scholar
  9. 9.
    Vergote I, Robertson JFR, Kleeberg U, Burton G, Osborne CK, Mauriac L: Postmenopausal women who progress on fulvestrant ('Faslodex ') remain sensitive to further endo-crine therapy. Breast Cancer Res Treat 79: 207–211, 2003Google Scholar
  10. 10.
    Robertson JFR, Howell A, Abram P, Lichinitser M, Elledge R: Fulvestrant versus tamoxifen for the first-line treatment of advanced breast cancer (ABC) in postmeno-pausal women. Ann Oncol 13 (Suppl. 5): 46, 2002 (abstract 164O)Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Sandra Franco
    • 1
    • 2
  • Alejandra Perez
    • 1
  • Elizabeth Tan-chiu
    • 1
  • Cynthia Frankel
    • 1
  • Charles L. Vogel
    • 1
  1. 1.Cancer Research NetworkFloridaUSA
  2. 2.Breast Cancer InstituteHollywoodUSA

Personalised recommendations